BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1689405)

  • 1. The endogenous induction of tumor necrosis factor serum (TNS) for the adjuvant postoperative immunotherapy of cancer--changes in immunological markers of the blood.
    Abe Y; Miyake M; Miyazaki T; Horiuchi A; Kimura S
    Jpn J Surg; 1990 Jan; 20(1):19-26. PubMed ID: 1689405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Subsets of peripheral blood lymphocytes and tumor infiltrating lymphocytes in cancer patients received chemotherapy].
    Mitachi Y; Murakawa Y; Okuno M; Kambe M; Kanamaru R; Takahasi H; Wakui A
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):482-8. PubMed ID: 2138871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocytic subpopulation changes after open and laparoscopic cholecystectomy: a prospective and comparative study on 38 patients.
    Cristaldi M; Rovati M; Elli M; Gerlinzani S; Lesma A; Balzarotti L; Taschieri AM
    Surg Laparosc Endosc; 1997 Jun; 7(3):255-61. PubMed ID: 9194291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination immunotherapy with OK-432, recombinant granulocyte-colony-stimulating factor and recombinant interleukin-2 for human hepatocellular carcinoma.
    Himoto T; Watanabe S; Nishioka M; Maeba T; Tanaka S; Saito M
    Cancer Immunol Immunother; 1996 Feb; 42(2):127-31. PubMed ID: 8620522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Changes on hosts' immunological response in HCC patients treated with transcatheter arterial embolization (TAE)].
    Komiyama K
    Nihon Shokakibyo Gakkai Zasshi; 1992 Oct; 89(10):2594-603. PubMed ID: 1328726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Transcatheter arterial embolization with hepatic arterial induction of endogenous TNF in hepatocellular carcinoma].
    Takekoshi H; Oyama R
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2845-8. PubMed ID: 2476966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment.
    Yamaguchi Y; Ohshita A; Kawabuchi Y; Hihara J; Miyahara E; Noma K; Toge T
    Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A double blind study of the evaluation of the optimal dose and its frequency in oral administration of OK-432 (Picibanil) by immunological parameters (the 1st report)].
    Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S
    Nihon Gan Chiryo Gakkai Shi; 1990 Apr; 25(4):799-811. PubMed ID: 2196311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lentinan potentiates immunity and prolongs the survival time of some patients.
    Matsuoka H; Seo Y; Wakasugi H; Saito T; Tomoda H
    Anticancer Res; 1997; 17(4A):2751-5. PubMed ID: 9252710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Studies on usefulness of postoperative adjuvant chemotherapy with lentinan in patients with gastrointestinal cancer].
    Tanabe H; Imai N; Takechi K
    Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1657-67. PubMed ID: 2230448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction by OK-432 of lymphokine activated killer precursor cells in hepatocellular carcinoma.
    Aramaki M; Kim YI; Shimoda K; Nakashima K; Okada K; Kobayashi M
    Hepatogastroenterology; 1994 Aug; 41(4):363-6. PubMed ID: 7959572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Disseminated and circulating tumor cells in gastrointestinal oncology].
    Vegas H; André T; Bidard FC; Ferrand FR; Huguet F; Mariani P; Pierga JY
    Bull Cancer; 2012 May; 99(5):535-44. PubMed ID: 22531892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Observation on natural killer cell activity in gastric cancer patients and effect of nonspecific immunopotentiator administration on its postoperative reduction].
    Oshita H; Saji S; Sugiyama Y; Tanemura H; Sakata K; Tanaka S; Ito T
    Nihon Geka Gakkai Zasshi; 1985 Oct; 86(10):1417-25. PubMed ID: 4079897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The current status of chemo- or immunotherapy of gastrointestinal tumors].
    Schmidt M; Gropp C; Martini GA
    Internist (Berl); 1978 Dec; 19(12):692-9. PubMed ID: 217849
    [No Abstract]   [Full Text] [Related]  

  • 15. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome.
    Yamaguchi Y; Hihara J; Hironaka K; Ohshita A; Okita R; Okawaki M; Matsuura K; Nagamine I; Ikeda T; Ohara M; Hamai Y
    Oncol Rep; 2006 Apr; 15(4):895-901. PubMed ID: 16525677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma.
    Ohira M; Nishida S; Tryphonopoulos P; Tekin A; Selvaggi G; Moon J; Levi D; Ricordi C; Ishiyama K; Tanaka Y; Ohdan H; Tzakis AG
    Cell Transplant; 2012; 21(7):1397-406. PubMed ID: 22469170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-cancer effects of BRMs associated with nutrition in cancer patients].
    Nishihira T; Akimoto M; Mori S
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-3):1615-20. PubMed ID: 3382233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent hepatocellular carcinoma cells with stem cell-like properties: possible targets for immunotherapy.
    Xu X; Xing B; Hu M; Xu Z; Xie Y; Dai G; Gu J; Wang Y; Zhang Z
    Cytotherapy; 2010 Apr; 12(2):190-200. PubMed ID: 19929456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of preoperative and postoperative enteral nutrition on postoperative nutritional status and immune function of gastric cancer patients.
    Ding D; Feng Y; Song B; Gao S; Zhao J
    Turk J Gastroenterol; 2015 Mar; 26(2):181-5. PubMed ID: 25835119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.
    Liyanage UK; Moore TT; Joo HG; Tanaka Y; Herrmann V; Doherty G; Drebin JA; Strasberg SM; Eberlein TJ; Goedegebuure PS; Linehan DC
    J Immunol; 2002 Sep; 169(5):2756-61. PubMed ID: 12193750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.